Correlation between frataxin expression and contractility revealed by in vitro Friedreich’s ataxia cardiac tissue models engineered from human pluripotent stem cells
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Friedreich's ataxia (FRDA) is an autosomal recessive disease caused by a non-coding mutation in the first intron of the frataxin (FXN) gene that suppresses its expression. Compensatory hypertrophic cardiomyopathy, dilated cardiomyopathy, and conduction system abnormalities in FRDA lead to cardiomyocyte (CM) death and fibrosis, consequently resulting in heart failure and arrhythmias. Murine models have been developed to study disease pathology in the past two decades; however, differences between human and mouse physiology and metabolism have limited the relevance of animal studies in cardiac disease conditions. To bridge this gap, we aimed to generate species-specific, functional in vitro experimental models of FRDA using 2-dimensional (2D) and 3-dimensional (3D) engineered cardiac tissues from FXN-deficient human pluripotent stem cell-derived ventricular cardiomyocytes (hPSC-hvCMs) and to compare their contractile and electrophysiological properties with healthy tissue constructs. METHODS: Healthy control and FRDA patient-specific hPSC-hvCMs were derived by directed differentiation using a small molecule-based protocol reported previously. We engineered the hvCMs into our established human ventricular cardiac tissue strip (hvCTS) and human ventricular cardiac anisotropic sheet (hvCAS) models, and functional assays were performed on days 7-17 post-tissue fabrication to assess the electrophysiology and contractility of FRDA patient-derived and FXN-knockdown engineered tissues, in comparison with healthy controls. To further validate the disease model, forced expression of FXN was induced in FXN-deficient tissues to test if disease phenotypes could be rescued. RESULTS: Here, we report for the first time the generation of human engineered tissue models of FRDA cardiomyopathy from hPSCs: FXN-deficient hvCTS displayed attenuated developed forces (by 70-80%) compared to healthy controls. High-resolution optical mapping of hvCAS with reduced FXN expression also revealed electrophysiological defects consistent with clinical observations, including action potential duration prolongation and maximum capture frequency reduction. Interestingly, a clear positive correlation between FXN expression and contractility was observed (ρ > 0.9), and restoration of FXN protein levels by lentiviral transduction rescued contractility defects in FXN-deficient hvCTS. CONCLUSIONS: We conclude that human-based in vitro cardiac tissue models of FRDA provide a translational, disease-relevant biomimetic platform for the evaluation of novel therapeutics and to provide insight into FRDA disease progression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Bioengineered cardiac tissues, created from human pluripotent stem cell (hPSC)derived cardiomyocytes, have successfully modeled aspects of native human heart structure and function, 16 including cardiotoxic and therapeutic responses, 17,18 and phenotypic characteristics of genetic and acquired cardiomyopathies.19,20”
From Reversal of contractile defects by mediating calcium homeostasis in human mini-heart models of heart failure with preserved ejection fraction (HFpEF) leads to first-in-human gene therapy clinical trial (2024) · cites this paper as [20]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In contrast to prior cardiac disease modeling approaches focused on genetic mutations, 20,42,43 this study demonstrates the use of biologics for induction of disease without requiring patient-specific human induced pluripotent stem cells.”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Puccio, H., Simon, D., Cossée, M., Criqui-Filipe, P., Tiziano, F., Melki, J., Hindelang, C., Matyas, R., Rustin, P., & Koenig, M. (2001) · Nature Genetics · doi:10.1038/84818 · Cited by 738 · cited 1×
“One murine model based on conditional ablation of mouse Fxn results in complete knockout of Fxn in cardiac and skeletal muscle [23]; although this model presents an aggressive FRDA-like phenotype, including cardiomyopathy and mitochondrial defects, it does not mirror the human genotype of trinucleotide repeats, which…”
Mortality in Friedreich Ataxia
Tsou, A. Y., Paulsen, E. K., Lagedrost, S. J., Perlman, S. L., Mathews, K. D., Wilmot, G. R., Ravina, B., Koeppen, A. H., & Lynch, D. R. (2011) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2011.05.023 · Cited by 315
Al-Mahdawi, S., Pinto, R. M., Varshney, D., Lawrence, L., Lowrie, M. B., Hughes, S., Webster, Z., Blake, J., Cooper, J. M., King, R., et al. (2006) · Genomics · doi:10.1016/j.ygeno.2006.06.015 · Cited by 243
Advancing functional engineered cardiac tissues toward a preclinical model of human myocardium
Turnbull, I. C., Karakikes, I., Serrao, G. W., Backeris, P., Lee, J., Xie, C., Senyei, G., Gordon, R. E., Li, R. A., Akar, F. G., et al. (2014) · The FASEB Journal · doi:10.1096/fj.13-228007 · Cited by 184 · cited 1×
“Using hvCAS, we measured cellular action potential parameters and electrical conduction as a syncytium, and with 3D human ventricular cardiac tissue strips (hvCTS) that resemble cardiac trabecular muscles [16, 20, 21], we evaluated contractility.”
Self-citationGOFFART, S., VONKLEISTRETZOW, J., & WIESNER, R. (2004) · Cardiovascular Research · doi:10.1016/j.cardiores.2004.06.030 · Cited by 176
Miranda, C. J., Santos, M. M., Ohshima, K., Smith, J., Li, L., Bunting, M., Cossée, M., Koenig, M., Sequeiros, J., Kaplan, J., et al. (2002) · FEBS Letters · doi:10.1016/s0014-5793(02)02251-2 · Cited by 172
Hick, A., Wattenhofer-Donzé, M., Chintawar, S., Tropel, P., Simard, J. P., Vaucamps, N., Gall, D., Lambot, L., André, C., Reutenauer, L., et al. (2013) · Disease Models & Mechanisms · doi:10.1242/dmm.010900 · Cited by 154
Martelli, A., & Puccio, H. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00130 · Cited by 147
Self-citationUnderstanding the molecular mechanisms of Friedreich's ataxia to develop therapeutic approaches
Schmucker, S., & Puccio, H. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq165 · Cited by 143
Complex Tissue and Disease Modeling using hiPSCs
Passier, R., Orlova, V., & Mummery, C. (2016) · Cell Stem Cell · doi:10.1016/j.stem.2016.02.011 · Cited by 142 · cited 1×
“It is generally acknowledged that observations from 2dimensional (2D) biological assays do not necessarily translate to 3D systems [13, 14], and 3D cardiac engineered tissues have proven valuable in modeling cardiac diseases including hypertrophic cardiomyopathy [15, 16].”
Cited by
Wong, A. O.-T., Gurung, B., Wong, W. S., Mak, S. Y., Tse, W. W., Li, C. M., Lieu, D. K., Costa, K. D., Li, R. A., & Hajjar, R. J. (2021) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2020.12.014 · Cited by 16
Self-citationCosta, K. D., Wong, A. O. T., Mak, S. Y., Roberts, E. G., Keung, W., Correia, C., Walentinsson, A., Christoffersson, J., Cheung, A., Lieu, D. K., et al. (2024) · bioRxiv · doi:10.1101/2024.08.27.609034 · Cited by 5
Self-citation
Metadata
- Authors
- Wong, A. O.-T., Wong, G., Shen, M., Chow, M. Z.-Y., Tse, W. W., Gurung, B., Mak, S. Y., Lieu, D. K., Costa, K. D., Chan, C. W., Martelli, A., Nabhan, J. F., & Li, R. A.
- Affiliations
- Pfizer (United States) (US)
- Corresponding author
- Nabhan, Joseph F.
- Li, Ronald A.
- Venue
- Stem Cell Research & Therapy
- Published
- 2019-07-08
- Volume
- 10
- Issue
- 1
- Pages
- 203-203
- ISSN
- 1757-6512 (ISSN-L)
- PMC
- PMC6615274
- OpenAlex
- W2962158619
- Cited by
- 27
- References
- 28
- Citations by year
- 2026: 5 · 2025: 1 · 2024: 5 · 2023: 2 · 2022: 7 · 2021: 3 · 2020: 3 · 2019: 1
- FWCI
- 1.16
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
- Locations
- Stem Cell Research & Therapy (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Pfizer (Not applicable)
- Novoheart (Not applicable)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac electrophysiology and arrhythmias
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Genetic Neurodegenerative Diseases
- Keywords
- Friedreich's ataxia, frataxin, engineered heart tissue, human pluripotent stem cell-derived cardiomyocytes, cardiomyocyte contractility, cardiac electrophysiology, action potential duration prolongation, disease modeling, heart failure
- MeSH terms
- Frataxin, Action Potentials, Cell Differentiation, Cells, Cultured, Friedreich Ataxia, Heart Failure, Humans, Cardiomyopathies, Myocytes, Cardiac, Iron-Binding Proteins, Pluripotent Stem Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Correlation between frataxin expression and contractility revealed by in vitro Friedreich’s ataxia cardiac tissue models engineered from human pluripotent stem cells. https://app.cochat.ai/papers/10.1186/s13287-019-1305-y
- The paper
- Wong, A. O.-T., Wong, G., Shen, M., Chow, M. Z.-Y., Tse, W. W., Gurung, B., Mak, S. Y., Lieu, D. K., Costa, K. D., Chan, C. W., Martelli, A., Nabhan, J. F., & Li, R. A. (2019). Correlation between frataxin expression and contractility revealed by in vitro Friedreich’s ataxia cardiac tissue models engineered from human pluripotent stem cells. Stem Cell Research & Therapy. https://doi.org/10.1186/s13287-019-1305-y
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.